NEW YORK, April 19, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of TherapeuticsMD, Inc. (“TherapeuticsMD”) (NYSEMKT:TXMD) between July 7, 2016 and April 9, 2017. You are hereby notified that Levi & Korsinsky has commenced the action Paoli v. TherapeuticsMD, Inc., et al. (Case No. 9:17-cv-80473-RLR) in the USDC for the Southern District of Florida. To get more information go to:
http://www.zlk.com/pslra-sa/therapeuticsmd-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the class period, TherapeuticsMD engaged in a scheme to deceive the market and cause the Company’s stock to trade at artificially inflated prices. In particular, the complaint alleges that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-0004HR NDA.
On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food and Drug Administration had identified deficiencies in its NDA for TX-004HR. Following this news, shares of TherapeuticsMD fell more than 19% to close at $6.20 per share on April 10, 2017.
Take Action: if you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 



